Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 21;20(23):7312-24.
doi: 10.3748/wjg.v20.i23.7312.

Pathogenesis of liver cirrhosis

Affiliations
Review

Pathogenesis of liver cirrhosis

Wen-Ce Zhou et al. World J Gastroenterol. .

Abstract

Liver cirrhosis is the final pathological result of various chronic liver diseases, and fibrosis is the precursor of cirrhosis. Many types of cells, cytokines and miRNAs are involved in the initiation and progression of liver fibrosis and cirrhosis. Activation of hepatic stellate cells (HSCs) is a pivotal event in fibrosis. Defenestration and capillarization of liver sinusoidal endothelial cells are major contributing factors to hepatic dysfunction in liver cirrhosis. Activated Kupffer cells destroy hepatocytes and stimulate the activation of HSCs. Repeated cycles of apoptosis and regeneration of hepatocytes contribute to pathogenesis of cirrhosis. At the molecular level, many cytokines are involved in mediation of signaling pathways that regulate activation of HSCs and fibrogenesis. Recently, miRNAs as a post-transcriptional regulator have been found to play a key role in fibrosis and cirrhosis. Robust animal models of liver fibrosis and cirrhosis, as well as the recently identified critical cellular and molecular factors involved in the development of liver fibrosis and cirrhosis will facilitate the development of more effective therapeutic approaches for these conditions.

Keywords: Animal model; Cirrhosis; Cytokine; Hepatic stellate cells; Pathogenesis; Therapy; miRNA.

PubMed Disclaimer

References

    1. Melato M, Mucli E. Something new in liver cirrhosis epidemiology. Lancet. 1989;2:395–396. - PubMed
    1. Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145:375–82.e1-2. - PMC - PubMed
    1. Qua CS, Goh KL. Liver cirrhosis in Malaysia: peculiar epidemiology in a multiracial Asian country. J Gastroenterol Hepatol. 2011;26:1333–1337. - PubMed
    1. Naveau S, Perlemuter G, Balian A. [Epidemiology and natural history of cirrhosis] Rev Prat. 2005;55:1527–1532. - PubMed
    1. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000;31:1014–1018. - PubMed